

18 Jun 2018 | Analysis

QUOTED. June 18, 2018. Meilan Han.

by

Pulmonologist Meilan Han says results from the Liberate study – the first randomized controlled trial in the US to evaluate the effectiveness and safety of Pulmonx's *Zephyr* endobronchial valve in patients with severe emphysema – was exciting in that the amount of improvement amongst patients was clinically significant. Check out what she said about it here.

"Not only did they have a statistically significant number of patients with improvements in lung function and six-minute walk test and quality of life, but the amount of change is sort of within the range I think that most clinicians would believe is clinically significant. Based on these data, if this technology becomes available, I think both physicians and patients would be excited to see it." –Meilan Han, associate professor of internal medicine in the division of Pulmonary and Critical Care Medicine, University of Michigan

- Find out more: [*Market Intel: Promising Data At ATS2018 Inflate Hopes For Endobronchial Valves And New Device-Based COPD Therapies*](#)

[Click here](#) for a free trial of *Medtech Insight*